{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:59:48Z","timestamp":1785787188167,"version":"3.56.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,2]]},"DOI":"10.1097\/01.coc.0000045849.95834.6b","type":"journal-article","created":{"date-parts":[[2004,1,30]],"date-time":"2004-01-30T04:04:36Z","timestamp":1075435476000},"page":"14-18","source":"Crossref","is-referenced-by-count":29,"title":["Docetaxel Versus Paclitaxel for Adjuvant Treatment of Ovarian Cancer"],"prefix":"10.1097","volume":"27","author":[{"given":"Yvonne","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel I.","family":"Sorosky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"key":"R2-3-20210128","first-page":"356a","article-title":"Randomized Phase III Study of Cisplatin (CIS)\/Paclitaxel (PAC) Versus Carboplatin (CARBO)\/PAC in Optimal Stage III Epithelial Ovarian Cancer (OC): A Gynecologic Oncology Group Trial (GOG 158)","volume":"18","author":"Ozols","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"R3-3-20210128","first-page":"3","article-title":"Preclinical profile of docetaxel (taxotere); efficacy as a single agent and in combination","volume":"22","author":"Bissery","year":"1995","journal-title":"Semin Oncol"},{"key":"R4-3-20210128","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/jnci\/83.4.288","article-title":"Studies with RP 56976 (Taxotere): a semi-synthetic analog of Taxol","volume":"83","author":"Ringel","year":"1991","journal-title":"J Natl Cancer Inst"},{"key":"R5-3-20210128","first-page":"329","article-title":"Interaction of tubulin and cellular microtubules with Taxotere (RP56976), a new semisynthetic analog of Taxol","volume":"32","author":"Barasoain","year":"1991","journal-title":"Proc Am Assoc Cancer Res"},{"key":"R6-3-20210128","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1021\/jm00107a017","article-title":"Relationships between the structure of Taxol analogues and their antimitotic activity","volume":"34","author":"Gueritte-Voegelein","year":"1991","journal-title":"J Med Chem"},{"key":"R7-3-20210128","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1200\/JCO.2000.18.14.2733","article-title":"Docetaxel for patients with paclitaxel-resistant m\\)llerian carcinoma","volume":"18","author":"Verschraegen","year":"2000","journal-title":"J Clin Oncol"},{"key":"R8-3-20210128","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/S0959-8049(97)00363-8","article-title":"Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer\u2014an updated overview","volume":"33","author":"Kaye","year":"1997","journal-title":"Eur J Cancer"},{"key":"R9-3-20210128","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/jnci\/87.9.676","article-title":"Docetaxel: an active drug for treatment of advanced epithelial ovarian cancer","volume":"87","author":"Piccart","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"R10-3-20210128","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1200\/JCO.1994.12.11.2301","article-title":"Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer","volume":"12","author":"Francis","year":"1994","journal-title":"J Clin Oncol"},{"key":"R11-3-20210128","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1200\/JCO.1999.17.7.2069","article-title":"Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group","volume":"17","author":"Vasey","year":"1999","journal-title":"J Clin Oncol"},{"key":"R12-3-20210128","first-page":"202a","article-title":"Preliminary results of the SCOTROC Trial: a phase III comparison of paclitaxel-carboplatin (PC) and docetaxel-carboplatin (DC) as first-line chemotherapy for stage IC-IV epithelial ovarian cancer (EOC)","author":"Vasey","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"R14-3-20210128","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1200\/JCO.2000.18.20.3558","article-title":"2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines","volume":"18","author":"Ozer","year":"2000","journal-title":"J Clin Oncol"},{"key":"R15-3-20210128","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1006\/gyno.1997.4906","article-title":"Taxol hypersensitivity: rapid retreatment is safe and cost effective","volume":"68","author":"Olson","year":"1998","journal-title":"Gynecol Oncol"},{"key":"R16-3-20210128","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/BF00257742","article-title":"Early clinical studies with cis-diammine-1, 1-cyclobutanedicarboxylate platinum II","volume":"9","author":"Calvert","year":"1982","journal-title":"Cancer Chemother Pharmacol"},{"key":"R17-3-20210128","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1200\/JCO.1994.12.10.2066","article-title":"Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer","volume":"12","author":"Taylor","year":"1994","journal-title":"J Clin Oncol"},{"key":"R18-3-20210128","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.1992.10.5.706","article-title":"Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology group of a phase III randomized trial in stages III and IV ovarian cancer","volume":"10","author":"Alberts","year":"1992","journal-title":"J Clin Oncol"},{"key":"R19-3-20210128","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1200\/JCO.1992.10.5.718","article-title":"Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group","volume":"10","author":"Swenerton","year":"1992","journal-title":"J Clin Oncol"},{"key":"R20-3-20210128","first-page":"837","article-title":"Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum","volume":"2","author":"Kavanagh","year":"1996","journal-title":"Clin Cancer Res"},{"key":"R21-3-20210128","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1200\/JCO.2001.19.7.1901","article-title":"Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum","volume":"19","author":"Markman","year":"2001","journal-title":"J Clin Oncol"},{"key":"R22-3-20210128","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.2000.18.1.102","article-title":"Paclitaxel-associated hypersensitivity reactions: experience of the Gynecologic Oncology Program of the Cleveland Clinic Cancer Center","volume":"18","author":"Markman","year":"2000","journal-title":"J Clin Oncol"},{"key":"R23-3-20210128","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/00001813-200008000-00007","article-title":"Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity","volume":"11","author":"Moon","year":"2000","journal-title":"Anti Cancer Drugs"},{"key":"R24-3-20210128","first-page":"1332","article-title":"Docetaxel as an alternative to paclitaxel after acute hypersensitivity reactions","volume":"34","author":"Bernstein","year":"2000","journal-title":"Ann Pharm"},{"key":"R25-3-20210128","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s004320000157","article-title":"Neurotoxicity associated with a regimen of carboplatin (AUC 5\u20136) and paclitaxel (175 mg\/m2 over 3h) employed in the treatment of gynecologic malignancies","volume":"127","author":"Markman","year":"2001","journal-title":"J Cancer Res Clin Oncol"},{"key":"R26-3-20210128","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/bjc.1997.68","article-title":"Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin","volume":"75","author":"Hilkens","year":"1997","journal-title":"Br J Cancer"},{"key":"R27-3-20210128","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1525-1438.2001.11(suppl.1)sup1031.x","article-title":"The integration of docetaxel into first-line chemotherapy for ovarian cancer","volume":"11","author":"Kaye","year":"2001","journal-title":"Int J Gyn Cancer"},{"key":"R28-3-20210128","first-page":"2107","article-title":"Retrospective analysis of administration of a combination of docetaxel and carboplatin for advanced non-small cell lung cancer","volume":"21","author":"Bando","year":"2001","journal-title":"Anticancer Res"},{"key":"R29-3-20210128","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1054\/bjoc.2000.1572","article-title":"Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer","volume":"84","author":"Vasey","year":"2001","journal-title":"Br J Cancer"},{"key":"R30-3-20210128","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0169-5002(01)00280-X","article-title":"Cost-minimisation analysis of three regimens of chemotherapy (docetaxel-cisplatin, paclitaxel-cisplatin, paclitaxel-carboplatin) for advanced non-small-cell lung cancer","volume":"35","author":"Rubio-Terres","year":"2002","journal-title":"Lung Ca"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.coc.0000045849.95834.6B","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:05:16Z","timestamp":1785783916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000421-200402000-00003"}},"subtitle":["Case\u2013Control Analysis of Toxicity"],"short-title":[],"issued":{"date-parts":[[2004,2]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004]]}},"URL":"https:\/\/doi.org\/10.1097\/01.coc.0000045849.95834.6b","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2004,2]]}}}